Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Additionally, on April 1, 2024, a multi-state Medicaid pharmaceutical purchasing group added ELYXYB® to its purchasing pool to make it eligible for thirteen States’ Medicaid programs.
- Additionally, on April 1, 2024, a multi-state Medicaid pharmaceutical purchasing group added ELYXYB® to its purchasing pool to make it eligible for thirteen States’ Medicaid programs.
- Scilex believes that high deductibles and co-pay programs should not prevent patients from receiving the medications they need.
- Scilex co-pay programs are designed to help patients reduce their co-pay and out-of-pocket costs for their medications.
- For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .